MX2012012777A - Agentes de union del receptor nuclear. - Google Patents
Agentes de union del receptor nuclear.Info
- Publication number
- MX2012012777A MX2012012777A MX2012012777A MX2012012777A MX2012012777A MX 2012012777 A MX2012012777 A MX 2012012777A MX 2012012777 A MX2012012777 A MX 2012012777A MX 2012012777 A MX2012012777 A MX 2012012777A MX 2012012777 A MX2012012777 A MX 2012012777A
- Authority
- MX
- Mexico
- Prior art keywords
- increased
- levels
- weight gain
- obesity
- fat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos para la prevención y/o tratamiento de desórdenes metabólicos, obesidad post-menopáusica y condiciones asociadas con consumo de dieta alta en grasa incluyendo obesidad, ganancia de peso corporal, formación de masa grasa, reducción de contenido mineral óseo, ganacia de peso de tejido adiposo blanco, niveles de colesterol incrementados, niveles de leptina incrementados, resistencia a insulina, diabetes tipo II, niveles de glucosa en sangre incrementados, enfermedades inflamatorias, enfermedades cardiovasculares, condición de hígado graso (acumulación de grasa en hígado), niveles de proteína de desacoplamiento-1 (UCP-1) disminuidos y lipogénesis incrementada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/773,515 US9623021B2 (en) | 2007-01-22 | 2010-05-04 | Nuclear receptor binding agents |
PCT/US2011/035206 WO2011140228A1 (en) | 2010-05-04 | 2011-05-04 | Nuclear receptor binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012012777A true MX2012012777A (es) | 2013-04-24 |
Family
ID=44904060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012012777A MX2012012777A (es) | 2010-05-04 | 2011-05-04 | Agentes de union del receptor nuclear. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9623021B2 (es) |
EP (1) | EP2566330A4 (es) |
JP (2) | JP5792799B2 (es) |
KR (1) | KR20130061151A (es) |
CN (2) | CN106420745A (es) |
AU (1) | AU2011248154B2 (es) |
CA (1) | CA2798259A1 (es) |
IL (1) | IL222823A0 (es) |
MX (1) | MX2012012777A (es) |
RU (1) | RU2604666C2 (es) |
WO (1) | WO2011140228A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641013B (zh) * | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US20140297314A1 (en) | 2011-07-13 | 2014-10-02 | Gino Tutera | Systems and methods for calculating patient dosage |
KR102238970B1 (ko) | 2012-07-13 | 2021-04-09 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
CN104797933A (zh) | 2012-09-07 | 2015-07-22 | 阿尔伯达大学董事会 | 用于诊断发炎性肝病的方法和组合物 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP3010587A4 (en) * | 2013-06-18 | 2017-04-12 | Salk Institute for Biological Studies | Methods of treating muscular dystrophy |
PL229743B1 (pl) * | 2013-07-30 | 2018-08-31 | Narodowy Instytut Zdrowia Publicznego Panstwowy Zakl Higieny | Nowe pochodne kwasu 3,4-dihydroizochinolino-3- karboks ylowego o właściwościach przeciwnowotworowych, sposób ich syntezy, kompozycje farmaceutyczne zawierające te pochodne oraz ich zastosowanie |
AU2014320463B2 (en) * | 2013-09-11 | 2018-08-02 | Centre National De La Recherche Scientifique (Cnrs) | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection |
EP3126362B1 (en) | 2014-04-02 | 2022-01-12 | Intermune, Inc. | Anti-fibrotic pyridinones |
ES2718552T3 (es) | 2014-04-04 | 2019-07-02 | Pfizer | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4 |
CN104776687B (zh) * | 2014-09-05 | 2017-09-29 | 山东诚创医药技术开发有限公司 | 盐酸考来维仑聚合物的干燥方法 |
MX2017004943A (es) | 2014-10-15 | 2017-07-19 | Corcept Therapeutics Inc | Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides. |
KR101647348B1 (ko) * | 2014-12-30 | 2016-08-22 | 충남대학교산학협력단 | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
KR101800876B1 (ko) | 2015-10-28 | 2017-11-27 | 전남대학교 산학협력단 | 신규한 디아릴이소퀴놀론 또는 디아릴이소퀴놀린 화합물 및 이를 포함하는 약제학적 조성물 |
CA3032153A1 (en) | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
WO2018129470A1 (en) * | 2017-01-09 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Reversing deficient hedgehog signaling restores deficient skeletal regeneration |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
US11419832B2 (en) | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
EP3720433B1 (en) | 2017-12-04 | 2022-02-02 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating wilson disease |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2848356A (en) | 1954-08-30 | 1958-08-19 | Phillips Petroleum Co | Fungicides, their preparation and use |
CA1285951C (en) | 1985-10-28 | 1991-07-09 | Raj N. Misra | Naphthalenyl- and quinolinyl-amino substituted phenols |
US4921941A (en) | 1987-07-01 | 1990-05-01 | Schering Corporation | Orally active antiandrogens |
PT89545B (pt) | 1988-01-27 | 1994-02-28 | May & Baker Ltd | Processo para a preparacao de derivados da isoquinolinona |
US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
US5112869A (en) | 1989-04-04 | 1992-05-12 | Sloan-Kettering Institute For Cancer Research | Substituted 1-phenylnaphthalenes |
KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
ES2152938T3 (es) | 1992-09-28 | 2001-02-16 | Hoechst Ag | 1(2h)-isoquinolinas sustituidas antiarritmicas y cardioprotectoras, procedimiento para su produccion, medicamento que las contiene y su uso para la produccion de un medicamento para combatir fallos cardiacos. |
DE4333761A1 (de) | 1993-10-04 | 1995-04-06 | Luitpold Pharma Gmbh | Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
IT1307327B1 (it) | 1995-09-12 | 2001-10-30 | Smithkline Beecham Spa | Derivati idroisochinolinici sostituiti |
WO1997030047A1 (en) | 1996-02-17 | 1997-08-21 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
SE9600769D0 (sv) | 1996-02-28 | 1996-02-28 | Astra Ab | Compounds useful as analgesic |
JP3065949B2 (ja) | 1996-09-13 | 2000-07-17 | 日本アンテナ株式会社 | 多周波用アンテナ |
JP4256937B2 (ja) | 1996-12-27 | 2009-04-22 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | N−(ピリジニルアミノ)イソインドリン類および関連化合物 |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
AU6230098A (en) | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
NZ501650A (en) | 1997-05-13 | 2001-11-30 | Octamer Inc | Use of a pADPRT inhibitory compound that is not 3-aminobenzamide to treat inflammation and inflammatory diseases in mammals |
ES2318899T3 (es) | 1998-07-06 | 2009-05-01 | Bristol-Myers Squibb Company | Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina. |
JP2000072675A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2000019994A1 (en) | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
EP1163225A1 (en) | 1999-03-17 | 2001-12-19 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
JP2003506355A (ja) | 1999-08-03 | 2003-02-18 | アボット・ラボラトリーズ | カリウムチャンネル開放剤 |
AU1493401A (en) | 1999-09-30 | 2001-04-30 | Charlotte-Mecklenburg Hospital Authority | Treatment of carbon monoxide poisoning |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
ATE524170T1 (de) | 2000-02-14 | 2011-09-15 | Merck Sharp & Dohme | Östrogenrezeptor modulatoren |
AU2001256164A1 (en) | 2000-03-01 | 2001-09-12 | Akzo Nobel N.V. | Chroman derivatives as estrogenic compounds |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
ES2252273T3 (es) | 2000-08-23 | 2006-05-16 | Akzo Nobel N.V. | Derivados de 10-aril-11h-benzo(b)fluoreno y analogos destinados para una utilizacion medicinal. |
WO2002024655A1 (en) | 2000-09-20 | 2002-03-28 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
CA2321406A1 (en) | 2000-09-29 | 2002-03-29 | The Regents Of The University Of California | Restoration of perturbed barrier function by application of antiandrogens |
JP2004511501A (ja) | 2000-10-19 | 2004-04-15 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
JP4119246B2 (ja) | 2000-11-27 | 2008-07-16 | メルク エンド カムパニー インコーポレーテッド | エストロゲンレセプター修飾物質 |
WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
WO2002051821A1 (en) | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
WO2002058639A2 (en) | 2001-01-23 | 2002-08-01 | Merck & Co., Inc. | Pyranoflavonoid compounds and their use as estrogen receptor modulators |
US6943162B2 (en) | 2001-01-26 | 2005-09-13 | Smithkline Beecham Corporation | Piperazinyltriazines as estrogen receptor modulators |
SK10802003A3 (sk) | 2001-02-02 | 2004-05-04 | Takeda Chemical Industries, Ltd. | Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok |
US20040171006A1 (en) | 2001-04-27 | 2004-09-02 | Yonghong Xiao | Regulation of human prostaglandin-f synthase 1-like protein |
ATE355278T1 (de) | 2001-05-08 | 2006-03-15 | Kudos Pharm Ltd | Isochinolinon derivate als parp inhibitoren |
JP2004530684A (ja) | 2001-05-10 | 2004-10-07 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
DE60216275T2 (de) | 2001-05-25 | 2007-06-21 | Schering Corp. | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit |
US20030119800A1 (en) | 2001-06-18 | 2003-06-26 | Manolagas Stavros C. | Bone anabolic compounds and methods of use |
ES2274986T3 (es) | 2001-08-01 | 2007-06-01 | MERCK & CO., INC. | Derivados de benzimidazo 4,5-f/isoquinolinona. |
CA2456150A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
AU2002359283B2 (en) | 2001-11-19 | 2007-06-21 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
AU2002353739A1 (en) | 2001-11-28 | 2003-06-10 | Astrazeneca Ab | Therapeutic compounds |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
US6960607B2 (en) | 2001-12-13 | 2005-11-01 | Wyeth | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents |
TWI306450B (en) | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
US6903238B2 (en) | 2001-12-13 | 2005-06-07 | Wyeth | Substituted indenones as estrogenic agents |
TW200301107A (en) | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
WO2003053926A1 (fr) | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Nouveau derive de phenylalanine |
US6774248B2 (en) | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
US7015219B2 (en) | 2001-12-19 | 2006-03-21 | Bristol-Myers Squibb Company | 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators |
TW200408385A (en) | 2001-12-21 | 2004-06-01 | Akzo Nobel Nv | Tetrahydrobenzfluorene derivatives |
US6835745B2 (en) | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
US6630508B1 (en) | 2002-02-11 | 2003-10-07 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor β agonists |
AU2003211931A1 (en) | 2002-02-13 | 2003-09-04 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
AU2003212856A1 (en) | 2002-03-01 | 2003-09-16 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
PT1501819E (pt) | 2002-04-24 | 2010-11-11 | Merck Sharp & Dohme | Moduladores dos receptores de estrogéneo |
US20030220377A1 (en) | 2002-05-08 | 2003-11-27 | Richard Chesworth | Indole compounds and their use as estrogen agonists/antagonists |
CA2489906A1 (en) | 2002-06-06 | 2003-12-18 | University Of Rochester | Androgen receptor coregulators |
DE10230381A1 (de) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
US6893191B2 (en) | 2002-07-19 | 2005-05-17 | Creative Pultrusions, Inc. | Wale and retaining wall system |
CA2493234A1 (en) | 2002-07-24 | 2004-01-29 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
JPWO2004024694A1 (ja) | 2002-09-10 | 2006-01-05 | 杏林製薬株式会社 | 4−置換アリール−5−ヒドロキシイソキノリノン誘導体 |
US20060039974A1 (en) | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
AU2003267241A1 (en) | 2002-09-19 | 2004-04-08 | Merck And Co., Inc. | Method for treating depression and/or anxiety |
AU2003263402A1 (en) | 2002-09-20 | 2004-04-08 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
AU2003287076C1 (en) | 2002-10-15 | 2010-03-04 | University Of Tennessee Research Foundation | Heterocyclic selective androgen receptor modulators and methods of use thereof |
ATE540928T1 (de) | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
JP2006517807A (ja) | 2002-12-30 | 2006-08-03 | パーデュー・リサーチ・ファウンデーション | 中枢神経系の損傷の治療方法 |
WO2004073612A2 (en) | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Estrogen receptor modulators |
EP1604983A4 (en) | 2003-03-17 | 2008-06-25 | Takeda Pharmaceutical | Receptor Antagonists |
US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
ATE406373T1 (de) | 2003-04-21 | 2008-09-15 | Lilly Co Eli | Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta |
ATE457308T1 (de) | 2003-04-21 | 2010-02-15 | Lilly Co Eli | Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta |
WO2004103941A2 (en) | 2003-05-16 | 2004-12-02 | Wyeth | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
US7250440B2 (en) | 2003-08-12 | 2007-07-31 | Wyeth | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents |
DE602004028493D1 (de) | 2003-09-23 | 2010-09-16 | Merck Sharp & Dohme | Isochinolinon-kaliumkanalinhibitoren |
US7781457B2 (en) | 2003-09-23 | 2010-08-24 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
US7723352B2 (en) | 2003-09-23 | 2010-05-25 | Merck Sharp & Dohme | Isoquinolinone potassium channel inhibitors |
WO2005032590A1 (ja) | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
CA2539882A1 (en) | 2003-10-03 | 2005-04-21 | Portola Pharmaceuticals, Inc. | Substituted isoquinolinones |
WO2005051972A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
CA2546150A1 (en) | 2003-11-24 | 2005-10-20 | Merck & Co., Inc. | Estrogen receptor modulators |
PL1689410T3 (pl) | 2003-11-26 | 2008-10-31 | Bayer Schering Pharma Ag | Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu |
CA2555824C (en) * | 2004-02-13 | 2011-06-07 | Banyu Pharmaceutical Co., Ltd. | Fused-ring 4-oxopyrimidine derivative |
US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
US20070191438A1 (en) | 2004-04-06 | 2007-08-16 | Rohrer Susan P | Methods for the treatment of hypertension |
KR20070028400A (ko) | 2004-05-04 | 2007-03-12 | 아카디아 파마슈티칼스 인코포레이티드 | 에스트로겐 리셉터에 활성을 갖는 화합물 |
US20080015173A1 (en) | 2004-06-10 | 2008-01-17 | Blizzard Timothy A | Estrogen Receptor Modulators |
US20080032959A1 (en) | 2004-06-23 | 2008-02-07 | Alves Stephen E | Estrogen Receptor Modulators |
EP1773862A1 (en) | 2004-06-30 | 2007-04-18 | Merck & Co., Inc. | Estrogen receptor modulators |
CA2570518A1 (en) | 2004-07-01 | 2006-01-19 | Wyeth | Tetracyclic compounds as estrogen ligands |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
CN101072564A (zh) | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
EP1789420A2 (en) | 2004-09-07 | 2007-05-30 | Wyeth, A Corporation of the State of Delaware | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
ES2361031T3 (es) | 2004-10-18 | 2011-06-13 | Eli Lilly And Company | Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos. |
AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
BRPI0518874A2 (pt) | 2004-12-09 | 2008-12-16 | Merck & Co Inc | composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço |
US20060183652A1 (en) | 2004-12-10 | 2006-08-17 | Takashi Fujitsu | Lubricating oil composition |
CA2593097A1 (en) | 2004-12-31 | 2006-07-13 | Aventis Pharmaceuticals Inc. | Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis |
WO2006081152A2 (en) | 2005-01-24 | 2006-08-03 | Merck & Co., Inc. | Estrogen receptor modulators |
EP1853578A1 (en) | 2005-02-15 | 2007-11-14 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
AU2006214515A1 (en) | 2005-02-16 | 2006-08-24 | Wyeth | Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis |
US7482029B2 (en) | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
JP2008536835A (ja) | 2005-04-06 | 2008-09-11 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ジアリールアミン含有化合物および組成物、ならびにステロイドホルモン核受容体のモジュレータとしてのそれらの使用 |
US9763961B2 (en) | 2005-04-13 | 2017-09-19 | City Of Hope | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use |
WO2006116401A1 (en) | 2005-04-28 | 2006-11-02 | Bristol-Myers Squibb Company | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators |
NZ565878A (en) * | 2005-07-21 | 2010-04-30 | Reliance Life Sciences Pvt Ltd | 2,5-substituted 3-undecyl-1,4-benzoquinones |
US20070021495A1 (en) | 2005-07-25 | 2007-01-25 | Katzenellenbogen John A | Sulfonamides as selective estrogen receptor |
PT1910333E (pt) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
EP1943224B1 (en) | 2005-10-05 | 2011-07-27 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
WO2007053353A2 (en) | 2005-10-28 | 2007-05-10 | Wyeth | Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
US20070197488A1 (en) | 2005-11-29 | 2007-08-23 | Olaf Peters | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
KR101296264B1 (ko) | 2006-02-09 | 2013-08-14 | 암젠 리서치 (뮌헨) 게엠베하 | 전이성 유방암의 치료 |
AU2007214711A1 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
WO2007093364A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
EP1990335A4 (en) | 2006-03-02 | 2009-11-11 | Astellas Pharma Inc | 17-BETA-HSD-type-5 INHIBITOR |
WO2007137000A2 (en) | 2006-05-16 | 2007-11-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
WO2007149031A1 (en) | 2006-06-19 | 2007-12-27 | Astrazeneca Ab | Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2008016768A1 (en) | 2006-08-02 | 2008-02-07 | Roberta Diaz Brinton | Phytoestrogenic formulations and uses thereof |
US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
CN101641013B (zh) | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
GB0722779D0 (en) | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
US20100029734A1 (en) | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
CN102413692B (zh) | 2009-02-23 | 2015-01-07 | Gtx公司 | 雌激素受体配体及其使用方法 |
WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
-
2010
- 2010-05-04 US US12/773,515 patent/US9623021B2/en not_active Expired - Fee Related
-
2011
- 2011-05-04 JP JP2013509219A patent/JP5792799B2/ja not_active Expired - Fee Related
- 2011-05-04 MX MX2012012777A patent/MX2012012777A/es unknown
- 2011-05-04 WO PCT/US2011/035206 patent/WO2011140228A1/en active Application Filing
- 2011-05-04 RU RU2012151846/15A patent/RU2604666C2/ru not_active IP Right Cessation
- 2011-05-04 AU AU2011248154A patent/AU2011248154B2/en not_active Ceased
- 2011-05-04 CA CA2798259A patent/CA2798259A1/en not_active Abandoned
- 2011-05-04 CN CN201610438738.5A patent/CN106420745A/zh active Pending
- 2011-05-04 EP EP11778267.2A patent/EP2566330A4/en not_active Withdrawn
- 2011-05-04 KR KR1020127031669A patent/KR20130061151A/ko not_active Application Discontinuation
- 2011-05-04 CN CN2011800327709A patent/CN102970870A/zh active Pending
-
2012
- 2012-11-01 IL IL222823A patent/IL222823A0/en unknown
-
2015
- 2015-08-05 JP JP2015155050A patent/JP2016006095A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2011248154A1 (en) | 2012-11-29 |
EP2566330A4 (en) | 2013-11-06 |
CN102970870A (zh) | 2013-03-13 |
JP5792799B2 (ja) | 2015-10-14 |
CA2798259A1 (en) | 2011-11-10 |
JP2016006095A (ja) | 2016-01-14 |
JP2013525494A (ja) | 2013-06-20 |
CN106420745A (zh) | 2017-02-22 |
IL222823A0 (en) | 2012-12-31 |
US9623021B2 (en) | 2017-04-18 |
AU2011248154B2 (en) | 2016-03-03 |
RU2604666C2 (ru) | 2016-12-10 |
RU2012151846A (ru) | 2014-06-10 |
WO2011140228A1 (en) | 2011-11-10 |
US20100267767A1 (en) | 2010-10-21 |
EP2566330A1 (en) | 2013-03-13 |
KR20130061151A (ko) | 2013-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012012777A (es) | Agentes de union del receptor nuclear. | |
Caterson et al. | Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity | |
MX2013007189A (es) | Metodos y composiciones adecuados para manejar glucosa en sangre en animales. | |
WO2007092556A3 (en) | Method of using abscisic acid to treat and prevent diseases and disorders | |
IN2014CN04055A (es) | ||
MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
WO2012088519A3 (en) | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders | |
WO2011075539A3 (en) | Treatment of obesity or diabetes with bile acid sequestrants | |
WO2008054200A3 (en) | Use of nutritional compositions for preventing disorders | |
MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
UA106365C2 (ru) | Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2 | |
MX2009011359A (es) | Derivados de pirimidinona y sus metodos de uso. | |
MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
WO2005113016A3 (en) | Modulation of glucose-6-phosphatase translocase expression | |
WO2010151755A3 (en) | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 | |
MX2009003658A (es) | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. | |
WO2011031493A3 (en) | Galectin-3 and cardiac resynchronization therapy | |
WO2011031063A3 (ko) | 항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
Alpert | Exercise is just as important as your medication | |
NZ606236A (en) | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease | |
Andrade Júnior et al. | Short term testosterone replacement therapy improves libido and body composition | |
WO2011090265A3 (ko) | 신코닌을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 | |
WO2006084233A3 (en) | Modulation of endogenous aicar levels for the treatment of diabetes and obesity | |
Dynnyk et al. | Physical activity reduce hepatic apoptosis in patients with non-alcoholic fatty liver disease and visceral obesity | |
Hoyos et al. | From couch potato to gym junkie—CPAP may not be the answer |